Loncastuximab Shows Favorable Tolerability in Relapsed/Refractory DLBCL
Matthew S. McKinney, MD, discusses the tolerability observed in the LOTIS-2 trial of loncastuximab tesirine of patients with relapsed/refractory diffuse large B-cell lymphoma.